0.0111
전일 마감가:
$0.0111
열려 있는:
$0.0111
하루 거래량:
3,076
Relative Volume:
24.99
시가총액:
$N/A
수익:
-
순이익/손실:
$-13.24M
주가수익비율:
-0.00126
EPS:
-8.83
순현금흐름:
$-16.85M
1주 성능:
-95.41%
1개월 성능:
-95.41%
6개월 성능:
-97.91%
1년 성능:
-99.74%
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
VRPX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
VRPX
Virpax Pharmaceuticals Inc
|
0.0111 | 0 | 0 | -13.24M | -16.85M | -8.83 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
388.94 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.38 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
443.64 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
677.32 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
308.63 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Virpax Pharmaceuticals Inc 주식(VRPX)의 최신 뉴스
Promising Nanotechnology Stocks To Watch Now – July 16th - Defense World
Promising Nanotechnology Stocks To Watch NowJuly 16th - MarketBeat
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading Down 2.9% – Should You Sell? - Defense World
Promising Nanotechnology Stocks To Add to Your Watchlist – July 9th - Defense World
Top Nanotechnology Stocks To Follow NowJuly 10th - MarketBeat
Promising Nanotechnology Stocks To Add to Your WatchlistJuly 9th - MarketBeat
Nanotechnology Stocks To Watch Today – July 7th - Defense World
Nanotechnology Stocks To Research – July 3rd - Defense World
Best Nanotechnology Stocks To Add to Your WatchlistJune 16th - MarketBeat
Top Nanotechnology Stocks Worth WatchingJune 17th - MarketBeat
Best Nanotechnology Stocks To Keep An Eye OnJune 15th - MarketBeat
Nanotechnology Stocks To Watch NowJune 14th - MarketBeat
Promising Nanotechnology Stocks To ResearchJune 11th - MarketBeat
Nanotechnology Stocks To ResearchJune 8th - MarketBeat
Nanotechnology Stocks To Follow NowJune 9th - MarketBeat
Best Nanotechnology Stocks To Follow Today – May 31st - Defense World
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading 4.4% Higher – Still a Buy? - Defense World
Virpax Pharmaceuticals appoints new independent director - MSN
Virpax and Nanomerics Enter Technology License Agreement for Developing A Product for PTSD Treatment - StatNano
Promising Nanotechnology Stocks To Watch Now – May 7th - The AM Reporter
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading Up 5.5% – Here’s What Happened - Defense World
Virpax(R) Pharmaceuticals Announces Appointment of Michèle C. Linde, EVP, General Counsel - ACCESS Newswire
Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Large Increase in Short Interest - Defense World
Virpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology Conference - MSN
VRPX stock plunges to 52-week low, touches $1.07 - Investing.com Australia
Virpax Pharmaceuticals to be delisted from Nasdaq By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals stock plummets on Nasdaq delisting news By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals stock plummets on Nasdaq delisting news - Investing.com India
Virpax Pharmaceuticals to be delisted from Nasdaq - Investing.com
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split By Investing.com - Investing.com Australia
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split - Investing.com India
VRPX stock plunges to 52-week low of $0.12 amid market challenges - Investing.com Australia
Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals - Business Wire
Virpax Pharmaceuticals announces 1-for-25 reverse stock split By Investing.com - Investing.com South Africa
VRPX stock plunges to 52-week low of $0.12 amid market challenges By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals announces 1-for-25 reverse stock split - Investing.com India
Virpax Pharmaceuticals Announces Reverse Stock Split - Business Wire
Virpax Reports Positive Results From Dose Range Finding Study of Pain Relief Treatment in Beagle Dogs - MarketScreener
Virpax receives positive Probudur(TM) results for dose range study -March 18, 2025 at 05:34 pm EDT - Marketscreener.com
Virpax reports positive results in Probudur dog study By Investing.com - Investing.com Australia
Virpax reports positive results in Probudur dog study - Investing.com
Breakthrough: Virpax's 5-Day Pain Drug Passes Critical Safety Test - StockTitan
Virpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using MET - MSN
Virpax Pharmaceuticals stock hits 52-week low at $0.18 By Investing.com - Investing.com Australia
Virpax Pharmaceuticals Inc (VRPX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):